Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp.
(NYSE: NVRO ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital management," said Kevin Thornal , Nevro's CEO.
"We continue to make improvements in our commercial execution and allocation of marketing resources to address ongoing market challenges and return to top-line growth." "We are excited about our recent limited market launch of HFX AdaptivAITM, the only artificial intelligence (AI)-driven technology in spinal cord stimulation, which delivers responsive and personalized pain relief in real time. We anticipate the full market release of HFX AdaptivAI by the end of November," continued Thornal.
"We are also thrilled to receive regulatory approval to now offer our HFX iQ system in CE-marked countries in Europe . Our team worked tirelessly to achieve this milestone, and we look forward to the limited market release of HFX iQ in select regions of Eu.
